BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ito K, Shrank WH, Avorn J, Patrick AR, Brennan TA, Antman EM, Choudhry NK. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res 2012;47:2097-117. [PMID: 22998129 DOI: 10.1111/j.1475-6773.2012.01462.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Blankart KE, Lichtenberg FR. Are patients more adherent to newer drugs? Health Care Manag Sci 2020;23:605-18. [PMID: 32770286 DOI: 10.1007/s10729-020-09513-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Marquina C, Zomer E, Vargas-torres S, Zoungas S, Ofori-asenso R, Liew D, Ademi Z. Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. PharmacoEconomics 2020;38:1095-113. [DOI: 10.1007/s40273-020-00936-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
3 Ivers NM, Schwalm JD, Bouck Z, McCready T, Taljaard M, Grace SL, Cunningham J, Bosiak B, Presseau J, Witteman HO, Suskin N, Wijeysundera HC, Atzema C, Bhatia RS, Natarajan M, Grimshaw JM. Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial. BMJ 2020;369:m1731. [PMID: 32522811 DOI: 10.1136/bmj.m1731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
4 Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, Weinstein MC. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J 2019;214:77-87. [PMID: 31174054 DOI: 10.1016/j.ahj.2019.04.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
5 Doll JA, Hellkamp AS, Thomas L, Fonarow GC, Peterson E, Wang TY. The association of pre- and posthospital medication adherence in myocardial infarction patients. Am Heart J 2019;208:74-80. [PMID: 30580129 DOI: 10.1016/j.ahj.2018.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Khan MS, Roberts MS. Challenges and innovations of drug delivery in older age. Adv Drug Deliv Rev 2018;135:3-38. [PMID: 30217519 DOI: 10.1016/j.addr.2018.09.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
7 Araújo-Soares V, Hankonen N, Presseau J, Rodrigues A, Sniehotta FF. Developing Behavior Change Interventions for Self-Management in Chronic Illness: An Integrative Overview. Eur Psychol 2019;24:7-25. [PMID: 31496632 DOI: 10.1027/1016-9040/a000330] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
8 Sarfo FS, Sarfo-Kantanka O, Adamu S, Obese V, Voeks J, Tagge R, Sethi V, Ovbiagele B. Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial. Trials 2018;19:181. [PMID: 29540234 DOI: 10.1186/s13063-018-2564-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ivers N, Schwalm JD, Witteman HO, Presseau J, Taljaard M, McCready T, Bosiak B, Cunningham J, Smarz S, Desveaux L, Tu JV, Atzema C, Oakes G, Isaranuwatchai W, Grace SL, Bhatia RS, Natarajan M, Grimshaw JM. Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol. Am Heart J 2017;190:64-75. [PMID: 28760215 DOI: 10.1016/j.ahj.2017.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
10 Sarfo FS, Ovbiagele B. Stroke minimization through additive anti-atherosclerotic agents in routine treatment (SMAART): A pilot trial concept for improving stroke outcomes in sub-Saharan Africa. J Neurol Sci 2017;377:167-73. [PMID: 28477689 DOI: 10.1016/j.jns.2017.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
11 Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, Ebrahim S, Huffman MD. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017;3:CD009868. [PMID: 28263370 DOI: 10.1002/14651858.CD009868.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
12 Barlow DR, Higgins BT, Ozanne EM, Tosteson AN, Pearson AM. Cost Effectiveness of Operative Versus Non-Operative Treatment of Geriatric Type-II Odontoid Fracture. Spine (Phila Pa 1976) 2016;41:610-7. [PMID: 27018900 DOI: 10.1097/BRS.0000000000001275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Colonna AL, Byrge NR, Nelson SD, Nelson RE, Hunter MC, Nirula R. Nonoperative management of adhesive small bowel obstruction: what is the break point? The American Journal of Surgery 2016;212:1214-21. [DOI: 10.1016/j.amjsurg.2016.09.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
14 Bramlage P, Sims H, Minguet J, Ferrero C. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk. Eur J Prev Cardiolog 2016;24:297-310. [DOI: 10.1177/2047487316674817] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
15 Senekjian L, Nirula R, Bellows B, Nelson R. Interval Appendectomy: Finding the Breaking Point for Cost-Effectiveness. Journal of the American College of Surgeons 2016;223:632-43. [DOI: 10.1016/j.jamcollsurg.2016.07.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
16 Castellano JM, Bueno H, Fuster V. The cardiovascular polypill: clinical data and ongoing studies. Int J Cardiol 2015;201 Suppl 1:S8-14. [PMID: 26747391 DOI: 10.1016/S0167-5273(15)31027-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
17 Kirsch F. Economic Evaluations of Multicomponent Disease Management Programs with Markov Models: A Systematic Review. Value Health 2016;19:1039-54. [PMID: 27987631 DOI: 10.1016/j.jval.2016.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
18 Bansilal S, Castellano JM, Garrido E, Wei HG, Freeman A, Spettell C, Garcia-alonso F, Lizano I, Arnold RJ, Rajda J, Steinberg G, Fuster V. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. Journal of the American College of Cardiology 2016;68:789-801. [DOI: 10.1016/j.jacc.2016.06.005] [Cited by in Crossref: 123] [Cited by in F6Publishing: 100] [Article Influence: 20.5] [Reference Citation Analysis]
19 Doll JA, Wang TY, Choudhry NK, Cannon CP, Cohen DJ, Fonarow GC, Henry TD, Bhandary DD, Khan N, Davidson-Ray LD, Anstrom K, Peterson ED. Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. Am Heart J 2016;177:33-41. [PMID: 27297847 DOI: 10.1016/j.ahj.2016.04.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
20 Simon-tuval T, Neumann PJ, Greenberg D. Cost-effectiveness of adherence-enhancing interventions: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 2016;16:67-84. [DOI: 10.1586/14737167.2016.1138858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
21 Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. Circulation 2016;133:518-36. [DOI: 10.1161/circulationaha.115.018713] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 14.5] [Reference Citation Analysis]
22 Lauffenburger JC, Choudhry NK. Text Messaging and Patient Engagement in an Increasingly Mobile World. Circulation 2016;133:555-6. [PMID: 26769741 DOI: 10.1161/CIRCULATIONAHA.116.021182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
23 Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M, Fonarow GC, Peterson ED; TRANSLATE-ACS Study Investigators. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. Am Heart J 2015;170:62-9. [PMID: 26093865 DOI: 10.1016/j.ahj.2015.03.019] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 12.6] [Reference Citation Analysis]
24 Faria R, Barbieri M, Light K, Elliott RA, Sculpher M. The economics of medicines optimization: policy developments, remaining challenges and research priorities. Br Med Bull 2014;111:45-61. [PMID: 25190760 DOI: 10.1093/bmb/ldu021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
25 Laba T, Hayes A, Lo S, Peiris DP, Usherwood T, Hillis GS, Rafter N, Reid CM, Tonkin AM, Webster R, Neal BC, Cass A, Patel A, Rodgers A, Jan S. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia 2014;201:671-3. [DOI: 10.5694/mja14.00266] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
26 Castellano JM, Sanz G, Fernandez Ortiz A, Garrido E, Bansilal S, Fuster V. A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention. Journal of the American College of Cardiology 2014;64:613-21. [DOI: 10.1016/j.jacc.2014.06.009] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
27 Tonelli M. The Roads Less Traveled? Diverging Research and Clinical Priorities for Dialysis Patients and Those With Less Severe CKD. American Journal of Kidney Diseases 2014;63:124-32. [DOI: 10.1053/j.ajkd.2013.08.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
28 Gandjour A. Validation of models that estimate the cost-effectiveness of improving patient adherence. Value Health 2013;16:1170-1. [PMID: 24326171 DOI: 10.1016/j.jval.2013.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Desai NR, Choudhry NK. Impediments to adherence to post myocardial infarction medications. Curr Cardiol Rep 2013;15:322. [PMID: 23250659 DOI: 10.1007/s11886-012-0322-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]